Purple Biotech (PPBT) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Purple Biotech has successfully closed a $2.8 million registered direct offering of American Depositary Shares, with H.C. Wainwright & Co. acting as the exclusive placement agent. The funds will be used to advance the development of their oncology therapeutic candidates and support general corporate activities. Investors interested in biotech innovations and oncology therapies might find opportunities with Purple Biotech’s continued progress in overcoming tumor immune evasion and drug resistance.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.